Pulmonary hypertension is a group of disorders characterized by elevated mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance. To test our hypothesis that combining two drugs useful in experimental pulmonary hypertension, statins and dehydroepiandrosterone sulfate (DHEA S), is more effective than either agent alone, we induced pulmonary hypertension in adult male rats by exposing them to hypoxia (10%O2) for 3 weeks. We treated them with simvastatin (60 mg/l) and DHEA S (100 mg/l) in drinking water, either alone or in combination. Both simvastatin and DHEA S reduced mPAP (froma mean±s.d. of 34.4±4.4 to 27.6±5.9 and 26.7±4.8 mmHg, respectively), yet their combination was not more effective (26.7±7.9 mmHg). Differences in the degree of oxidative stress (indicated by malondialdehydeplasma concentration),the rate of superoxide production (electron paramagnetic resonance), or blood nitric oxide levels (chemiluminescence) did not explain the lack of additivity of the effect of DHEA S and simvastatin on pulmonary hypertension. We propose that the main mechanism of both drugs on pulmonary hypertension could be their inhibitory effect on 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, which could explain their lack of additivity.

Department of Physiology 2nd Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–D41. doi: 10.1016/j.jacc.2013.10.029. PubMed DOI

Corris PA, Seeger W. Call it by the correct name - pulmonary hypertension not pulmonary arterial hypertension: growing recognition of the global health impact for a well-recognized condition and the role of the Pulmonary Vascular Research Institute. Am J Physiol Lung Cell Mol Physiol. 2020;318:L992–L4. doi: 10.1152/ajplung.00098.2020. PubMed DOI

Davies JT, Delfino SF, Feinberg CE, Johnson MF, Nappi VL, Olinger JT, Schwab AP, Swanson HI. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights. 2016;9:13–29. doi: 10.4137/LPI.S37450. PubMed DOI PMC

Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002;166:1403–8. doi: 10.1164/rccm.200203-268OC. PubMed DOI

Katsiki N, Wierzbicki AS, Mikhailidis DP. Pulmonary arterial hypertension and statins: an update. Curr Opin Cardiol. 2011;26:322–6. doi: 10.1097/HCO.0b013e32834659bf. PubMed DOI

Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda L, Tuder RM, Johns RA, Hassoun PM. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1105–L10. doi: 10.1152/ajplung.00411.2006. PubMed DOI

Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003;108:1640–5. doi: 10.1161/01.CIR.0000087592.47401.37. PubMed DOI

Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev. 2000;80:1337–72. doi: 10.1152/physrev.2000.80.4.1337. PubMed DOI

Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, Ozaki H. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2005;25:2335–42. doi: 10.1161/01.ATV.0000186184.33537.48. PubMed DOI

Pei Y, Ma P, Wang X, Zhang W, Zhang X, Zheng P, Yan L, Xu Q, Dai G. Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur J Pharmacol. 2011;666:165–72. doi: 10.1016/j.ejphar.2011.05.035. PubMed DOI

Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis. 2004;15:251–8. doi: 10.1097/01.mca.0000131573.31966.34. PubMed DOI

Beltowski J. Statins and modulation of oxidative stress. Toxicol Mech Methods. 2005;15:61–92. doi: 10.1080/15376520590918766. PubMed DOI

Anand V, Garg S, Duval S, Thenappan T. A systematic review and meta-analysis of trials using statins in pulmonary arterial hypertension. Pulm Circ. 2016;6:295–301. doi: 10.1086/687304. PubMed DOI PMC

Rysz-Gorzynska M, Gluba-Brzozka A, Sahebkar A, Serban MC, Mikhailidis DP, Ursoniu S, Toth PP, Bittner V, Watts GF, Lip GY, Rysz J, Catapano AL, Banach M. Efficacy of statin therapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Sci Rep. 2016;6:30060. doi: 10.1038/srep30060. PubMed DOI PMC

Wang L, Qu M, Chen Y, Zhou Y, Wan Z. Statins have no additional benefit for pulmonary hypertension: a meta-analysis of randomized controlled trials. PLoS One. 2016;11:e0168101. doi: 10.1371/journal.pone.0168101. PubMed DOI PMC

Lu Y, Chang R, Yao J, Xu X, Teng Y, Cheng N. Effectiveness of long-term using statins in COPD - a network meta-analysis. Respir Res. 2019;20:17. doi: 10.1186/s12931-019-0984-3. PubMed DOI PMC

Zhao L, Sebkhi A, Ali O, Wojciak-Stothard B, Mamanova L, Yang Q, Wharton J, Wilkins MR. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J. 2009;34:948–57. doi: 10.1183/09031936.00143508. PubMed DOI

Lee DS, Kim YK, Jung YW. Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension. Korean Circ J. 2010;40:659–64. doi: 10.4070/kcj.2010.40.12.659. PubMed DOI PMC

Labrie F, Luu-The V, Labrie C, Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol. 2001;22:185–212. doi: 10.1006/frne.2001.0216. PubMed DOI

Celec P, Stárka L. Dehydroepiandrosterone - is the fountain of youth drying out? Physiol Res. 2003;52:397–407. PubMed

Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004;3:171–87. doi: 10.1016/j.arr.2003.05.001. PubMed DOI

Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Gαi2,3. J Biol Chem. 2002;277:21379–88. doi: 10.1074/jbc.M200491200. PubMed DOI

Bonnet S, Dumas-de-La-Roque E, Begueret H, Marthan R, Fayon M, Dos Santos P, Savineau J-P, Baulieu E-E. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci USA. 2003;100:9488–93. doi: 10.1073/pnas.1633724100. PubMed DOI PMC

Yuan X-J. Voltage gated K+ currents regulate resting membrane potential and [Ca2+]i in pulmonary artery myocytes. Circ Res. 1995;77:370–8. doi: 10.1161/01.RES.77.2.370. PubMed DOI

Hampl V, Huang JM, Weir EK, Archer SL. Activation of the cGMP-dependent protein kinase mimics the stimulatory effect of nitric oxide and cGMP on calcium-gated potassium channels. Physiol Res. 1995;44:39–44. PubMed

Ochi R, Chettimada S, Kizub I, Gupte SA. Dehydroepiandrosterone inhibits ICa,L and its window current in voltage-dependent and -independent mechanisms in arterial smooth muscle cells. Am J Physiol Heart Circ Physiol. 2018;315:H1602–H13. doi: 10.1152/ajpheart.00291.2018. PubMed DOI PMC

Rom WN, Harkin T. Dehydroepiandrosterone inhibits the spontaneous release of superoxide radical by alveolar macrophages in vitro in asbestosis. Environ Res. 1991;55:145–56. doi: 10.1016/S0013-9351(05)80171-9. PubMed DOI

Žaloudíková M, Vytášek R, Rašková M, Vízek M, Uhlík J, Hampl V. The effect of exposure to hypoxia on superoxide formation by alveolar macrophages is indirect. Life Sci. 2019;236:116864. doi: 10.1016/j.lfs.2019.116864. PubMed DOI

Žaloudíková M, Vytášek R, Vajnerová O, Hniličková O, Vízek M, Hampl V, Herget J. Depletion of alveolar macrophages attenuates hypoxic pulmonary hypertension but not hypoxia-induced increase in serum concentration of MCP-1. Physiol Res. 2016;65:763–8. doi: 10.33549/physiolres.933187. PubMed DOI

Ventetuolo CE, Baird GL, Barr RG, Bluemke DA, Fritz JS, Hill NS, Klinger JR, Lima JA, Ouyang P, Palevsky HI, Palmisciano AJ, Krishnan I, Pinder D, Preston IR, Roberts KE, Kawut SM. Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. Am J Respir Crit Care Med. 2016;193:1168–75. doi: 10.1164/rccm.201509-1785OC. PubMed DOI PMC

Hampl V, Bíbová J, Povýšilová V, Herget J. Dehydroepiandrosterone sulfate reduces experimental pulmonary hypertension in rats. Eur Respir J. 2003;21:862–5. doi: 10.1183/09031936.03.00084503. PubMed DOI

Oka M, Karoor V, Homma N, Nagaoka T, Sakao E, Golembeski SM, Limbird J, Imamura M, Gebb SA, Fagan KA, McMurtry IF. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc Res. 2007;74:377–87. doi: 10.1016/j.cardiores.2007.01.021. PubMed DOI PMC

Zhang YT, Xue JJ, Wang Q, Cheng SY, Chen ZC, Li HY, Shan JJ, Cheng KL, Zeng WJ. Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure. Life Sci. 2019;219:82–9. doi: 10.1016/j.lfs.2018.12.056. PubMed DOI

Silva AF, Sousa-Nunes F, Faria-Costa G, Rodrigues I, Guimaraes JT, Leite-Moreira A, Henriques-Coelho T, Negrao R, Moreira-Goncalves D. Effects of chronic moderate alcohol consumption on right ventricle and pulmonary remodelling. Exp Physiol. 2021;106:1359–72. doi: 10.1113/EP088788. PubMed DOI

Jakoubek V, Hampl V. Alcohol and fetoplacental vasoconstrictor reactivity. Physiol Res. 2018;67:509–13. doi: 10.33549/physiolres.933609. PubMed DOI

Herget J, Paleček F. Pulmonary arterial blood pressure in closed chest rats. Changes after catecholamines, histamine and serotonin. Arch Int Pharmacodyn Ther. 1972;198:107–17. PubMed

Beitl E, Baňasová A, Miková D, Hampl V. Nitric oxide as an indicator for severity of injury in polytrauma. Bratisl Med J. 2016;117:217–20. doi: 10.4149/BLL_2016_041. PubMed DOI

Agarwal R, Chase SD. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B. 2002;775:121–6. doi: 10.1016/S1570-0232(02)00273-8. PubMed DOI

Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316–28. doi: 10.1016/j.numecd.2005.05.003. PubMed DOI

Chalupsky K, Kracun D, Kanchev I, Bertram K, Gorlach A. Folic acid promotes recycling of tetrahydrobiopterin and protects against hypoxia-induced pulmonary hypertension by recoupling endothelial nitric oxide synthase. Antioxid Redox Signal. 2015;23:1076–91. doi: 10.1089/ars.2015.6329. PubMed DOI PMC

McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol. 2007;293:L933–L40. doi: 10.1152/ajplung.00310.2006. PubMed DOI

Sun X, Ku DD. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol. 2008;294:H801–H9. doi: 10.1152/ajpheart.01112.2007. PubMed DOI

Stroes E. Statins and LDL-cholesterol lowering: an overview. Curr Med Res Opin. 2005;21:S9–S16. doi: 10.1185/030079905X59102. PubMed DOI

Kopec G, Waligora M, Tyrka A, Jonas K, Pencina MJ, Zdrojewski T, Moertl D, Stokwiszewski J, Zagozdzon P, Podolec P. Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. Sci Rep. 2017;7:41650. doi: 10.1038/srep41650. PubMed DOI PMC

Dumas de La Roque E, Savineau JP, Metivier AC, Billes MA, Kraemer JP, Doutreleau S, Jougon J, Marthan R, Moore N, Fayon M, Baulieu EE, Dromer C. Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study. Ann Endocrinol. 2012;73:20–5. doi: 10.1016/j.ando.2011.12.005. PubMed DOI

Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2011;20:243–53. doi: 10.1183/09059180.00006511. PubMed DOI PMC

all MK, Waypa GB, Mungai PT, Nielsen JM, Czech L, Dudley VJ, Beussink L, Dettman RW, Berkelhamer SK, Steinhorn RH, Shah SJ, Schumacker PT. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. Am J Respir Crit Care Med. 2014;189:314–24. doi: 10.1164/rccm.201302-0302OC. PubMed DOI PMC

Peng W, Hoidal JR, Farrukh IS. Role of a novel KCa opener in regulating K+ channels of hypoxic human pulmonary vascular cells. Am J Respir Cell Mol Biol. 1999;20:737–45. doi: 10.1165/ajrcmb.20.4.3390. PubMed DOI

Sehra D, Sehra S, Sehra ST. Cardiovascular pleiotropic effects of statins and new onset diabetes: is there a common link: do we need to evaluate the role of KATP channels? Expert Opin Drug Saf. 2017;16:823–31. doi: 10.1080/14740338.2017.1338269. PubMed DOI

Chen Y, Zhang H, Liu H, Cao A. Mechanisms of simvastatin-induced vasodilatation of rat superior mesenteric arteries. Biomed Rep. 2016;5:491–6. doi: 10.3892/br.2016.756. PubMed DOI PMC

Teisseyre A, Uryga A, Michalak K. Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells. J Mol Struct. 2021;1230:129905. doi: 10.1016/j.molstruc.2021.129905. PubMed DOI PMC

Cheong A, Li J, Sukumar P, Kumar B, Zeng F, Riches K, Munsch C, Wood IC, Porter KE, Beech DJ. Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers. Cardiovasc Res. 2011;89:282–9. doi: 10.1093/cvr/cvq305. PubMed DOI PMC

Yang S, Gu YY, Jing F, Yu CX, Guan QB. The effect of statins on levels of dehydroepiandrosterone (DHEA) in women with polycystic ovary syndrome: a systematic review and meta-analysis. Med Sci Monit. 2019;25:590–7. doi: 10.12659/MSM.914128. PubMed DOI PMC

Pascale RM, Simile MM, De Miglio MR, Nufris A, Seddaiu MA, Muroni MR, Danni O, Rao KN, Feo F. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase activity and gene expression by dehydrocpiandrosterone in preneoplastic liver nodules. Carcinogenesis. 1995;16:1537–42. doi: 10.1093/carcin/16.7.1537. PubMed DOI

Hampl V, Bíbová J, Ošťádalová I, Povýšilová V, Herget J. Gender differences in the long-term effects of perinatal hypoxia on the pulmonary circulation in rats. Am J Physiol Lung Cell Mol Physiol. 2003;285:L386–L92. doi: 10.1152/ajplung.00389.2002. PubMed DOI

Goldman N, Glei DA. Sex differences in the relationship between DHEAS and health. Exp Gerontol. 2007;42:979–87. doi: 10.1016/j.exger.2007.05.005. PubMed DOI PMC

Karp I, Chen S-F, Pilote L. Sex differences in the effectiveness of statins after myocardial infarction. CMAJ. 2007;176:333–8. doi: 10.1503/cmaj.060627. PubMed DOI PMC

Mechanisms Controlling the Behavior of Vascular Smooth Muscle Cells in Hypoxic Pulmonary Hypertension